| Uterine Leiomyoma |
1 |
0.9 |
| Bone Density |
0 |
0.34 |
| Dysfunctional Uterine Bleeding |
0 |
0.29 |
| Bone |
0 |
0.28 |
| Gonadotropin-Releasing Hormone (GnRH) Antagonist |
0 |
0.27 |
| Patient Safety |
0 |
0.25 |
| Bone Densitometry |
0 |
0.23 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.22 |
| Adverse Effects |
0 |
0.2 |
| Breast Cancer |
0 |
0.18 |
| Contraception |
0 |
0.18 |
| Spine |
0 |
0.18 |
| Biliary Disease |
0 |
0.15 |
| Food and Drug Administration (FDA) |
0 |
0.15 |
| Blood |
0 |
0.13 |
| Pain Management |
0 |
0.1 |
| Progestin |
0 |
0.1 |
| Thromboembolism |
0 |
0.1 |
| Menorrhagia |
0 |
0.08 |
| Pituitary Gland |
0 |
0.08 |
| Ultrasonography |
0 |
0.08 |
| Pelvic Pain |
0 |
0.07 |
| Breast Cancer History |
0 |
0.06 |
| Osteoporosis |
0 |
0.06 |
| Ablation |
0 |
0.05 |
| Alopecia |
0 |
0.05 |
| Amenorrhea |
0 |
0.05 |
| Artery |
0 |
0.05 |
| Cancer |
0 |
0.05 |
| Estrogen |
0 |
0.05 |
| Jobs |
0 |
0.05 |
| laparotomy |
0 |
0.05 |
| Lumbar Spine |
0 |
0.05 |
| Pain |
0 |
0.05 |
| Radiofrequency Ablation (RFA) |
0 |
0.05 |
| Surgery |
0 |
0.05 |
| Tumor |
0 |
0.05 |
| Femoral Neck |
0 |
0.04 |
| Liver Disease |
0 |
0.04 |
| Liver Tumor |
0 |
0.04 |
| Abdomen |
0 |
0.03 |
| Anemia |
0 |
0.03 |
| Anxiety |
0 |
0.03 |
| Anxiety Disorder |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Breast |
0 |
0.03 |
| Cervical Region |
0 |
0.03 |
| Cholecystitis |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Depression |
0 |
0.03 |
| Dorsum |
0 |
0.03 |
| Embolization |
0 |
0.03 |
| Hemoglobin |
0 |
0.03 |
| Hysterectomy |
0 |
0.03 |
| Intrauterine Device |
0 |
0.03 |
| Liver |
0 |
0.03 |
| Menopause |
0 |
0.03 |
| Meta-Analysis |
0 |
0.03 |
| Minerals |
0 |
0.03 |
| Mood Swings |
0 |
0.03 |
| Oligomenorrhea |
0 |
0.03 |
| Pregnancy |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Thrombosis |
0 |
0.03 |
| Vagina |
0 |
0.03 |